Vitrectomy with removal of the internal limiting membrane in chronic diabetic macular oedema

Dillinger, P; Mester, U

doi:10.1007/s00417-003-0849-8

Cited by 67 publications

(55 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Prospective studies reported 43% 6 and 52% 5 of eyes with DMO gained two or more lines of visual acuity following ILM peeling. Performing vitrectomy without ILM peeling in eyes with no evident vitreomacular traction, LaHeij et al 3 reported resolution of DMO in 21 of 21 eyes while Tachi and Ogino 4 reported resolution of DMO in 57 of 58 eyes.…”

Section: Discussionmentioning

confidence: 99%

“…2 The role of vitreoretinal traction in the pathogenesis of DMO as well as positive impact of vitrectomy and removal of internal limiting membrane (ILM) on DMO has been known. [3][4][5][6] Triamcinolone-assisted posterior vitreous separation is also beneficial for DMO. 7,8 We compared the efficacy of indocyanine green (ICG)-assisted ILM peeling and triamcinolone-assisted posterior vitreous separation in terms of best-corrected visual acuity (BCVA) in DMO.…”

Section: Introductionmentioning

confidence: 99%

“…7 Diabetic eyes had a greater chance of having a residual vitreous cortex after posterior vitreous removal, as demonstrated by the triamcinalone-assisted vitrectomy. 6 Failure to recognise true posterior vitreous hyaloid may contribute to continued morbidity after vitrectomy. Residual vitreous on the retina left untreated during vitrectomy may serve as a scaffold for continued neovascular proliferation and release inflammatory mediators leading to complications of proliferative diabetic retinopathy.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Comparison of ICG-assisted ILM peeling and triamcinolone-assisted posterior vitreous removal in diffuse diabetic macular oedema

Bardak

Çekıç

Tiğ

2005

Eye

View full text Add to dashboard Cite

Aim To compare the effect of indocyanine green (ICG)-assisted internal limiting membrane (ILM) peeling and triamcinolone acetonide-assisted posterior vitreous removal on visual acuity in patients with diffuse diabetic macular oedema (DMO). Methods In total, 24 patients with diffuse DMO who underwent pars plana vitrectomy were included in this study. In all, 11 patients (mean age 57 years) were performed ICGassisted ILM peeling; while 13 patients (mean age 54 years) underwent triamcinoloneassisted posterior vitreous removal. Patients from two different treatment regimens were compared in terms of best-corrected visual acuity (BCVA) at postoperative sixth months. Results In ICG-assisted ILM peeling group, preoperative BCVA (1.370.4, mean7SD, logMAR) improved postoperatively to 0.970.5 (P ¼ 0.011). In eyes underwent triamcinoloneassisted posterior vitreous removal, baseline BCVA of 1.470.4 improved to 1.070.5 (P ¼ 0.007). There was no difference between baseline as well as postoperative sixth-month BCVA results of both groups (P ¼ 0.59 and P ¼ 0.57, respectively). Conclusions Triamcinolone-assisted posterior vitreous removal and ICG-assisted ILM peeling have the same effect in terms of postoperative BCVA in patients with diffuse DMO.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Comparison of ICG-assisted ILM peeling and triamcinolone-assisted posterior vitreous removal in diffuse diabetic macular oedema

Bardak

Çekıç

Tiğ

2005

Eye

View full text Add to dashboard Cite

show abstract

“…However, although a recent large prospective study showed reduced oedema, only a minority of patients experienced any visual improvement. 25 A recent randomised trial of vitrectomy for macular oedema in the absence of visible traction (but with attached gel) has shown no benefit in the treatment group compared with controls treated with further grid laser. 26 The use of intravitreal triamcinolone has become very popular over the last 2 years for a number of conditions, including diffuse diabetic macular oedema.…”

Section: How Should We Treat Macular Oedema?mentioning

confidence: 99%

Progressive changes in diabetics and their management

Aylward

2005

Eye

View full text Add to dashboard Cite

The prevalence of diabetic retinopathy is increasing worldwide due to an increasing number, and prolonged survival, of diabetic patients. Many effective treatments for different types and stages of retinopathy exist. However, there is patchy delivery of care, inconsistent screening, and unresolved questions about several management questions. This article discusses the current state of knowledge about therapeutics in diabetic retinopathy, and highlights areas where further studies and evidence base is required.

show abstract

“…100/178 eyes (56.2%) demonstrated an acuity improvement of two or more lines at final follow-up. 24,29,30,32,39,[47][48][49] The proportion of eyes in these studies that improved by more than two lines ranged from 50 to 78%.…”

Section: Introductionmentioning

confidence: 99%